Rapaflo
Product Images NDC 54868-6173

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rapaflo (NDC 54868-6173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rapaflo (silodosin) 8mg X 30 Capsules (6173)

This information appears to be a label of a RAPAFLO BHG CAP medication, distributed by Physicians Total Care. It contains the National Drug Code (NDC) and the Lot number and Expiration Date of the medication. However, it does not include any information about the dosage, indications, or contraindications of the medication. Therefore, it is not possible to provide a full description of the medication based solely on this text.*

FDA Label Image

Silodosin Structural Formula. (Rapaflo Silodosin Capsules 1)

FDA Label Image

Figure 1 Mean (±sd) Silodosin Steady State Plasma Concentration-time Profile In Healthy Target-aged Subjects Following Silodosin 8 mg Once Daily With Food (Rapaflo Silodosin Capsules 2)

Not available.*

FDA Label Image

Figure 2 Mean Change From Baseline In Ipss Total Score By Treatment Group And Visit In Study 1 (Rapaflo Silodosin Capsules 3)

FDA Label Image

Figure 3 Mean Change From Baseline In Ipss Total Score By Treatment Group And Visit In Study 2 (Rapaflo Silodosin Capsules 4)

This appears to be a statistical analysis report of a study measuring the change from baseline in PSS (Perceived Stress Scale) total score. The result shows a statistically significant change (p<0.0001). However, due to the presence of seemingly random characters and incomplete phrases, it may be difficult to interpret this text with certainty.*

FDA Label Image

Figure 4 Mean Change From Baseline In Qmax (ml/sec) By Treatment Group And Visit In Study 1 (Rapaflo Silodosin Capsules 5)

FDA Label Image

Figure 5 Mean Change From Baseline In Qmax (ml/sec) By Treatment Group And Visit In Study 2 (Rapaflo Silodosin Capsules 6)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.